Concepedia

Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study

Marie Desplats, Tristan Pascart, Germain Jelin, Laurène Norberciak, Peggy Philippe, Éric Houvenagel, Vincent Goëb, René-Marc Flipo

Clinical Rheumatology · 2017 · 34 citations · 14 references

DOI

Concepts

References

14

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Xavier Pivot, Joseph Gligorov, Volkmar Müller et al. · Annals of Oncology · 2014 · 176 citations · Full text

, , +15

Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients with Relapsed Multiple Myeloma.

PubMed · 2016 · 158 citations

, , +14

Treatment choices, preferences and decision‐making by patients with rheumatoid arthritis

Frances Chilton, RAYMOND A. COLLETT · Musculoskeletal Care · 2007 · 149 citations

, , +15

Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)

Gerd R Burmester, Andrea Rubbert‐Roth, Alain Cantagrel et al. · Annals of the Rheumatic Diseases · 2015 · 123 citations · Full text

, , +16

Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort

James Bluett, Catharine Morgan, Layla Thurston et al. · Lara D. Veeken · 2014 · 105 citations · Full text

, , +17